"Liraglutide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
- NN 2211
- 2211, NN
Below are MeSH descriptors whose meaning is more general than "Liraglutide".
Below are MeSH descriptors whose meaning is more specific than "Liraglutide".
This graph shows the total number of publications written about "Liraglutide" by people in this website by year, and whether "Liraglutide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Liraglutide" by people in Profiles.
Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ. 2022 10 03; 379:e070717.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation. 2022 02 22; 145(8):575-585.
Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats. Diabetes. 2017 07; 66(7):2007-2018.
Liraglutide-induced autoimmune hepatitis. JAMA Intern Med. 2014 Jun; 174(6):984-7.
Restoring Insulin Secretion (RISE): design of studies of ?-cell preservation in prediabetes and early type 2 diabetes across the life span. Diabetes Care. 2014; 37(3):780-8.
Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):33B-41B.